# Research Corporation Technologies

> Research Corporation Technologies is a VC fund backing Biotechnology. See 29 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Tucson, United States
- Total investments: 29
- Last investment: Oct 2025
- Lead investor: 45%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/research-corporation-technologies/about/
- Website: http://www.rctech.com

Research Corporation Technologies is a VC fund in Tucson focused on Biotechnology and Health Care. Ogechison Ventures is a company that was founded by youths after leaving college to engage themselves in research as a form of giving back to the community. The Company also engages in community education projects in a bid to improve education standards in poverty stricken areas

## Contacts

5 contacts available for Research Corporation Technologies. Shizune tracks 3 team members at Research Corporation Technologies. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/research-corporation-technologies?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 11 | 38% |
| Health Care | 9 | 31% |
| Medical Device | 7 | 24% |
| Medical | 6 | 21% |
| Pharmaceutical | 6 | 21% |

18 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 7 | 24% |
| Series C | 6 | 21% |
| Series B | 5 | 17% |
| Funding Round | 4 | 14% |
| Seed | 1 | 3% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 18 | 62% |
| United Kingdom | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Christopher Martin | Sr. Vice President & CFO | 0 | https://shizune.co/investors/profile/christopher-martin-8e5d |
| John Roop | Managing Director | 0 | https://shizune.co/investors/profile/john-avi-roop |
| Chad Souvignier | Vice President | 3 | https://shizune.co/investors/profile/chad-souvignier |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Codis | Codis is a contract development and manufacturing organization (CDMO) specializing in commercial spray drying drying and particle engineering for enhanced bioavailability, high-performance materials, and pharmaceutical supply. |  | Private Equity | Oct 16, 2025 |  |
| Pheon Therapeutics | Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.The company was founded in 2022 and is based in London,England. | $120M | Series B | May 21, 2024 |  |
| S2 Genomics | S2 Genomics is developing spatial sequencing technology solutions for processing solid tissues for single-cell applications. It enables automated processing of raw tissues into single cells or nuclei for genomics and cell biology studies. The company's vision is to provide products that process raw tissues into samples ready for genomicanalyses.S2 Genomics was founded in 2016 and is headquartered in Livermore, CA. | $16M | Series A | Jan 23, 2024 |  |
| iotaMotion | IotaMotion standardizes cochlear implant insertion expanding access to cochlear interventions for surgeons and patients. Its open-platform robotic-assisted system aims to decrease surgical variability by controlling the speed and acceleration of electrode insertion. | $12M | Series A | Jul 26, 2023 |  |
| Pheon Therapeutics | Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.The company was founded in 2022 and is based in London,England. | $68M | Series A | Sep 28, 2022 |  |
| Halo Labs | Halo Labs (formerly Optofluidics) is a venture-backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing, and microfluidics.Its investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced ResearchProjects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.The company was founded in 2011 and headquartered in Pennsylvania, United States. | $7M | Series C | Jul 08, 2022 |  |
| seqWell | SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory services. It features a technology platform that serves as a transformative library prep technology that allows for simple, scalable multiplexing of 100s to 1000s of samples without time- and cost-consuming normalization.The company was foundedin 2014 and headquartered in Massachusetts, United States. | $7M | Series C | Mar 29, 2022 |  |
| Pheon Therapeutics | Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.The company was founded in 2022 and is based in London,England. |  | Seed | Jan 01, 2022 |  |
| Q'Apel Medical | Q'Apel Medical designs access device technology for neurovascular interventions and unmet clinical needs. The company was founded in 2016 and is headquartered in Fremont, California. | $22M | Series C | Feb 11, 2021 |  |
| Halo Labs | Halo Labs (formerly Optofluidics) is a venture-backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing, and microfluidics.Its investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced ResearchProjects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.The company was founded in 2011 and headquartered in Pennsylvania, United States. | $12M | Series B | Apr 06, 2020 |  |

10 of 29 investments shown.

## Co-investors
- [BroadOak Capital Partners](https://shizune.co/investors/profile/broadoak-capital-partners) — VC Fund, 9 deals together
- [California Technology Ventures](https://shizune.co/investors/profile/california-technology-ventures) — VC Fund, 4 deals together
- [Aphelion Capital](https://shizune.co/investors/profile/aphelion-capital) — VC Fund, 3 deals together
- [BioAdvance](https://shizune.co/investors/profile/bioadvance) — VC Fund, 3 deals together
- [Atlas Venture](https://shizune.co/investors/profile/atlas-venture) — VC Fund, 2 deals together
- [Brandon Capital](https://shizune.co/investors/profile/brandon-capital-partners) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [Life Science VC Funds in United Kingdom](https://shizune.co/investors/life-science-vc-funds-united-kingdom)

## FAQ

### What does Research Corporation Technologies invest in?

Research Corporation Technologies invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Series A and Series C stage. Most of the 29 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Research Corporation Technologies?

Public channels for Research Corporation Technologies include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Research Corporation Technologies?

The team at Research Corporation Technologies includes Christopher Martin (Sr. Vice President & CFO), John Roop (Managing Director) and Chad Souvignier (Vice President). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co